Catherine Teeselink
Family · Anchorage, AKNPI 1992472161
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,430 of the $1,726 with a category attached, or 82.8%. It is spread thinly across 33 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations.
Across 62 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$183
- Johnson & Johnson$146
- Incyte Corporation$143
- AbbVie$138
- Seagen Inc.$118
- Novartis$117
- plus $881 from 27 others
What the payments were for
- Food & beverage$1,43083%
- Education$29617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $183 |
| Johnson & Johnson | 3 | $146 |
| Incyte Corporation | 3 | $143 |
| AbbVie | 5 | $138 |
| Seagen Inc. | 2 | $118 |
| Novartis | 5 | $117 |
| E.r. Squibb & Sons, L.L.C. | 5 | $102 |
| Merck | 4 | $84 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Astellas Pharma US Inc | 2 | $62 |
| Genentech USA, Inc. | 2 | $47 |
| Deciphera Pharmaceuticals Inc. | 1 | $42 |
| Exelixis Inc. | 2 | $38 |
| Rigel Pharmaceuticals, Inc. | 1 | $34 |
| Bristol Myers Squibb | 2 | $32 |
| Tersera Therapeutics LLC | 1 | $30 |
| Sanofi | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| CTI Biopharma Corp. | 1 | $25 |
| Gilead | 1 | $24 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Pfizer | 1 | $24 |
| Foundation Medicine, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,726 in reported general payments places this provider in the 85th percentile of 315 family providers in Alaska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 24 | $473 |
| Dexamethasone | 12 | $197 |
| Prochlorperazine Maleate | 14 | $118 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Other family in Anchorage
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Marisha DietersAnchorage$6K
- Christine HooverAnchorage$6K
- Leigh KeeferAnchorage$5K
- Sara GeraciAnchorage$4K
- Christine SaganAnchorage$4K
- Bethany BuchananAnchorage$4K
- Natasha SherrillAnchorage$4K
- Katherine HardyAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.